Journal article
Parathyroid hormone for the treatment of osteoporosis: a systematic review
Abstract
BACKGROUND: Human parathyroid hormone (hPTH)(1-34) was approved in 2004 for the treatment of severe osteoporosis. Members of the Osteoporosis Canada clinical guidelines committee conducted a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of hPTH for fracture prevention in postmenopausal women and men with osteoporosis.
METHODS: We searched MEDLINE, EMBASE, HTA, Current Contents and the Cochrane …
Authors
Cranney A; Papaioannou A; Zytaruk N; Hanley D; Adachi J; Goltzman D; Murray T; Hodsman A
Journal
Canadian Medical Association Journal, Vol. 175, No. 1, pp. 52–59
Publisher
Joule
Publication Date
July 4, 2006
DOI
10.1503/cmaj.050929
ISSN
0820-3946